User:Mr. Ibrahem/Lusutrombopag
Jump to navigation
Jump to search
 | |
| Clinical data | |
|---|---|
| Pronunciation | loo" soo trom' boe pag |
| Trade names | Mulpleta, Mulpleo, Lusutrombopag Shionogi, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618043 |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Thrombopoietin receptor agonist[1] |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C29H32Cl2N2O5S |
| Molar mass | 591.54 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) | |
Lusutrombopag, sold under the brand name Mulpleta among others, is a medication used to treat low platelets due to chronic liver disease.[2] It is used before surgery.[1] It is taken by mouth.[1]
Common side effects include headache.[2] Other side effects may include nausea, portal vein thrombosis, and rash.[3] It is a thrombopoietin receptor agonist which increases platelet numbers.[1][3]
Lusutrombopag was approved in the United States in 2018 and Europe in 2019.[2][3] In the United Kingdom a course of treatment costs the NHS about £800.[1] In the United States this amount costs about 8,900 USD.[4]
References
[edit]- ^ a b c d e f BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1080. ISBN 978-0857114105.
- ^ a b c d e "Lusutrombopag Monograph for Professionals". Drugs.com. Archived from the original on 17 June 2020. Retrieved 24 November 2021.
- ^ a b c d "Mulpleo EPAR". European Medicines Agency (EMA). Archived from the original on 17 June 2020. Retrieved 17 June 2020.
- ^ "Mulpleta Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 April 2021. Retrieved 24 November 2021.